Atacand Approval Provides Alternative To ACE Inhibitors For Heart Failure

AstraZeneca's angiotensin receptor blocker Atacand can be used as an alternative to angiotensin-converting enzyme inhibitors in reducing risk of cardiovascular mortality and hospitalization in heart failure patients